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balloon to prevent cerebral emboli. Six symptomatic patients had 7 PTAs (6
carotids, 1 vertebral).
Pt. # Angioplasty Transcrania Stenosis Complications Stenosis
Technique Doppler Pre~Post 3 m F/U
1 Protected 73 emboli 90%--.20% none 10%
2 Protected 40 emboli 90%~ 0% none 0%
3 Active Perf. no window 95%~O% none 0%
4 Active Perf. 10 emboli 99%---+0% none 0%
5 Active Perf. no window 99%--+0% hemorrh--.death
6 Standard no window 100%-+30%-+ none pendin9
(vertebral) 5tent-+0%
Active Perf. 70%--)o-dissec, none pending
(carotid) 20%-+ 5tent--+ 0%
Maintenance of cerebral perfusion during PTA by "active" perfusion and
cardiac pacing allows prolonged balloon inflations which minimize residual
stenosis; when feasible, TCD monitoring is a valuable adjunct. Ongoing stud-
ies with more patients will elucidate the value of this approach for carotid
angioplasty.
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Treatment of Superficial Femoral Artery Occlusion by
Percutaneous Revascularizatlon of Ipsilateral Iliac
Artery Stenosis
Waqar Khan, Robert Schainfeld, Ann Pieczek, Kenneth Rosenfield, Jeffrey M. Isner.
St. Elizabeth's Medical Center, Boston, MA Tufts University School of Medicine, Boston,
MA
Systolic Blood Pressure
N Baseline 24 hr 1 mo 6 mo
Total cohort 39 177 ± 22 138 ± 20* 158 ± 30** 152 ± 25*
Responders (R) 25 184 ± 22 140 ± 23* 160 ± 32* 143 ± 21*
Non-responders (NR) 14 166 ± 19 134± 11* 157 ± 30 167 ± 25
*p < 0.0001, **p < 0.001 versus baseline BP
A significant (:::15%) improvement in SBP and/or DBP was measured in
86% of all patients 24 hours after stent implantation. At one and 6 months,
63% had sustained improvement in both SBP and DBP and were long-term
responders. A sustained BP improvement 6 months after stenting was pre-
dicted by older patient age, more severe hypertension, and larger reference
vessel diameter (p < 0.05). Not predictive of a favorable response to stent-
ing was sex, number of HTN medications, unilateral versus bilateral disease,
baseline serum Cr, BUN, or 6 month angiographic (:::50% diameter) resteno-
sis.
Conclusion: Renal artery stenting results in immediate BP control in the
majority patients studied, however, this BP improvement is sustained in only
63% of patients. Multi-variant analysis indicates that older patients with more
severe hypertension and larger renal arteries are more likely to receive a sus-
tained benefit from renal artery stenting.
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1796-5\ Stentlng of Renal Artery Stenosis: One-Year Followup
Tanvir K. Bajwa, Yoseph Shalev, Donald H. Schmidt University of Wisconsin,
Milwaukee, WI
*p < 0.05; values listed are pre- and 12 months post-procedure
No RestenosisBilateralUnilateral
Central vein occlusion is a common cause of morbidity in patients with up-
per extremity hemodialysis (HD) access sites and a history of ipsilateral in-
dwelling central lines. We analyzed the results of two percutaneous treat-
ments, balloon angioplasty (PTA) and stenting (S) that were used to relieve
symptomatic venous occlusion (arm edema, pain) and improve dialysis effi-
ciency (venous pressure and recirculation fraction). Group I consisted of 26
patients (13 men, 13 women, mean age ~ 62 ± 14.3), with de novo lesions
(innominate = 5, subclavian = 21) who underwent PTA. Group II consisted of
13 patients from Group I who underwent stent implantation (6 Palmaz stents,
7 Wallstents) for failed PTA due to suboptimal angioplasty results (n = 5) or
restenosis In = 8). We retrospectively compared the acute and long-term
clinical success and restenosis rates in these two treatment groups. Acute
success was defined as resolution of symptoms and resumption of dialy-
sis. Restenosis was defined as >50% stenosis by angiography. Long-term
success @ mean follow-up 14 months was defined as continued dialysis
without symptomatic venous occlusion or dialysis graft failure.
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Comparison of Stenting and PTA for Central Venous
Stenosis In Hemodialysis Patients
Peter Wassmer, Shabblr Dharamsey, Reynaldo Mulingtapang, SylVia Griffin,
Sam Money, Stephen Jenkins, Christopher White, Stephen Ramee. Ochsner Clinic,
New Orleans. LA; Health Care International, Glasgow, Scotland
Complications: Two patients developed pseudoaneurysm of left brachial
artery, which required percutaneous closure.
Conclusions: 1) Renal artery stenting can be performed with a low com-
plication rate, 2) In the majority of patients, symptomatic improvement was
achieved and maintained over a 12-month period and the number of antihy-
pertensive medications required decreased, and 3) Based on our study, we
would recommend renal artery stenting as the therapeutic option of choice
for symptomatic renal artery stenosis.
Creatinine (mg%) 2.1 ± 1.1 to 15 ± 0.9 2.5 ± 0.7 to 1.5 ± 0.6 2.1 ± 0.6 to 1.5
Diastolic BP ImmHg) 95 ± 10 to 80± S* 9O± 9 to SO ± 5* 90±7 to SO± 2*
No. of Meds. 3.2 ± 1to 1.1 ± 09* 2.9 ± 1 to 20 ± 0.5* 3.1 ± 1to 1.5 ± 1.0'
Palmaz-Schatz stents were deployed in 55 renal arteries (articulated in 30 and
nonarticulated in 25) of 45 pts (35 unilateral. 10 bilateral). Forty of the patients
were male and 5 were female (mean age 65 ± 5 years). 20/45 (44%) pts had
associated diabetes mellitus and coronary artery disease. We retrospectively
analyzed clinical outcome (renal functions, blood pressure, and number of
antihypertensive medications) at 6 and 12 months. Six month angiographic
followup was available in 25/45 pts (56%) and showed a restenosis rate of
5/25 (20%).
To evaluate the acute and chronic blood pressure (BP) response after renal
artery stent implantation, we prospectively studied 39 patients (14 men, 25
women, mean age = 67 ± 1O) with hypertension IHTN) refractory to medical
therapy and atherosclerotic renal artery stenosis I:::70%) who were treated
with balloon angioplasty and deployment of a stainless steel, non-articulated,
balloon expandable Palmaz stent. Twenty three (59%) patients had unilateral
stenosis, 14 (36%) had bilateral disease, and 2 (5%) had a solitary kidney. The
mean number of anti-hypertensive medications was 2.5 before treatment.
BP was recorded at baseline, 24 hrs., and at 1, 3, and 6 months after stent
implantation. Patients were classified either as responders (R), defined as
a ::: 15% drop in systolic (SBP) and/or diastolic blood pressure (DBP) from
baseline Bp, or non-responders (NR) based on their 6 month BP result.
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Acute and Long-term Effect of Renal Artery Stentlng
on Blood Pressure Control In Patients with
Atherosclerotic Renovascular Hypertension
Dinesh Shaw, Christopher White, Tyrone Collins, Arun Karsan, Melissa Facundus,
Richard Milani, Stephen Ramee. Ochsner Clinic, New Orleans; Health Care
International, Glasgow, Scotland
The acute and long-term results of percutaneous revascularization of the
lower extremities are typically superior for inflow (iliac) than distal (super-
ficial femoral artery SFA, popliteal, or infrapopliteal disease). Accordingly, we
investigated the utility of performing percutaneous revascularization for only
inflow (iliac) lesions in pts with both inflow as well as distal disease. We
treated 43 limbs in 36 pts (28 M, 8 F, age mean ± SD = 69 ± 8 yrs) with
the combination of SFA occlusion and ipsilateral iliac artery lesions by percu-
taneous revascularization of the iliac artery lesion only. Ten lesions involved
the common iliac artery, 18 involved both the common and the external iliac
arteries, and 15 consisted of external iliac artery stenosis. All pts were symp-
tomatically Rutherford class 3 and/or above. Mean ankle-brachial index (ABI)
pre-procedure was 0.55 ± 0.19. Ipsilateral iliac artery stenosis, determined
by quantitative angiography, was 80 ± 12%. All iliac lesions were treated
with percutaneous transluminal angioplasty (PTA) ± stent placement. Post-
PTA, iliac artery stenosis decreased to 8 ± 8%. Of the 43 treated limbs, 40
(93%) were associated with improvement by at least one Rutherford class.
One month post-procedure, mean ABI improved to 0.63 ± 0.191p < 0.009).
Complications were limited to 1 instance of arterial dissection which was
successfully treated with a stent. Six-month follow-up was available on 24/43
limbs; 19/24 (79%) continued to show improved symptoms measured by
Rutherford class. ABI's were remeasured at six months in 22 pts, and 18/22
(82%) showed improved ABI compared to baseline. Conclusion: Percuta-
neous revascularization limited to iliac artery stenosis in patients with ipsilat-
eral superficial femoral artery occlusion, by augmenting arterial inflow via a
patent profunda, is frequently sufficie'1t to produce clinical improvement of
disabling symptoms.
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travenous histamine (a vasopressorl. Thrombi were present in 19 of 34 aor-
tic plaques but none of 11 aortic sections from the normal rabbits. The 34
plaques and 11 normal sections were stained with antibody to tissue factor.
While none of the normal specimens had luminal surface tissue factor, it was
found on the surface of 17/19 (87%) of plaques with thrombi and 7/15 (45%)
of plaques without thrombi (p = 0.009).
r- p<O.001 -I
I r- p<0.01--,
I 17119
Conclusion: Plaques associated with thrombi were significantly more likely
to have luminal tissue factor than those without thrombi. These findings sup-
port the importance of tissue factor as a link between atherosclerosis and
thrombosis.
0111
Normal No Thrombi Thrombi
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Restoration of Thromboresistance in Injured Aortic
Segments by a Novel Nitric Oxide Donor
Tasneem Z. Naqvi, Michael C. Fishbein, Bojan Cercek, Arun M. Thomas, Mia
D. Molloy, Lina Badimon, Prediman K. Shah. Thomas C. Hutsell. Sanjay Kaul.
Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA: Comedicus
Incorporated, Minneapolis, MN
Endothelium-derived nitric oxide (NO) is one of the principal mediators of
thromboresistance in intact blood vessels. To determine whether repletion
of NO would restore thromboresistance in injured arterial segments, we in-
vestigated the effect of a novel short-lived NO donor - NO adduct of N,N'-
dimethylhexanediamine (DMHD/NO) on arterial injury-induced thrombosis
in an ex vivo rabbit carotid-jugular arteriovenous shunt model. Segments
of porcine aortic subendothelium (endothelium-deficient but intact internal
elastic lamina) and media, simulating mild and deep arterial injury, respec-
tively, were placed in a Badimon perfusion chamber and exposed to flowing
arterial blood from hypercholesterolemic (He) rabbits (cholesterol of 431 ±
187 mg/dL. n = 5) for 10 minutes at a shear rate of 1700/s (typical of mild
coronary stenosis). Thrombus volume was quantified in control and treated
segments by morphometry of histological sections. Treatment consisted of
DMHD/NO 10.01 /tM) and phosphate buffered saline as control. Thrombus
formation was minimal in subendothelium (8 ± 4/tm3//tm 2 of exposed area),
whereas media developed large thrombi (78 ± 15 /tm3//tm 2 (p = O.OOli.
DMHD/NO strikingly reduced thrombus volume in media by 85 ± 5% to 15
± 6 /tm3//tm 2, thereby effectively reversing thrombus formation to that in
subendothelium. Infusion of saline had no effect on thrombus formation.
Mean arterial pressure fell by about 3% after infusion of DMHD/NO.
Conclusion: In this ex vivo model of arterial thrombosis 1) deeply injured-
arterial segments (media) were highly thrombogenic and mildly injured-
arterial segments Isubendotheliuml were relatively thromboresistant. and 2)
DM HD/NO, a novel nitric oxide donor, effectively restored thromboresistance
in deeply injured-arterial segments without producing significant systemic
hemodynamic effects.
The presence of residual mural thrombus (MT) predisposes to recurrent
thrombotic vessel occlusion. To compare the benefits of different antithrom-
botic and anti platelet agents we studied the growth of thrombus on a pre-
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Comparative Effects of Heparin, Aspirin, and Hirudin
on Thrombus Growth on Fresh Mural Thrombus:
Deaggregation of Mural Thrombus by Specific
Thrombin Inhibition
Beat J. Meyer 1, Juan J. Badimon, John 1. Fallon, Valentin Fuster, James
H. Chesebro, Lina Badimon 1University Hospital Bern, Switzerland: Mount Sinai
Medical Center. New York
N Acute Restenosis Repeat PTA Long-term
Success Stent. Surgery Success
Group I 26 80% 82% 76% 30%
Group II 13 100% 23% 23% 84%
p-vaJue 0.17 <0.001 <0.008 <0.005
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Differential Expression of Tissue Factor Protein in
Directional Atherectomy Specimens from Patients
with Stable and Unstable Coronary Syndromes
Brian H. Annex, Stephen M. Denning, Keith Channon, Michael H. Sketch, Jr.,
Richard S. Stack, Kevin G. Peters Duke University Medical Center. Durham, NC
Tissue factor (TF) is a cell membrane-associated protein that catalyzes the
rate-limiting step of the exttinsic coagulation pathway, which is the major
source of thrombin production in-vivo. To examine the potential role that
TF may play in the pathogenesis of different coronary syndromes, we stud-
ied directional coronary atherectomy specimens ftom 57 patients, using im-
munohistochemical techniques. Patients were classified according to their
admission diagnosis as having either an unstable coronary syndrome, which
required the presence of rest angina or post-infarction 1<1 week) angina,
or stable coronary syndromes which included stable, progressive and new-
onset angina without rest chest pain. Lesions were also classified as a de-
novo or a restenosis lesion. Frozen sections were examined for the presence
of TF using a murine IgG monoclonal antibody against human tissue fac-
tor. Samples were read independently by two investigators without knowl-
edge of the clinical information. The results were expressed dichotomously
as positive or negative using human skin sections as a positive control and
a nonsense murine monoclonal antibody as a negative control. Statistical
analysis were performed using a Chi-Square or Fischer's Exact Test. For the
entire study group, TF was detected in 15 (45%) of 33 patients with unstable
coronary syndromes versus only 3 (13%1 of 24 patients with stable coronary
syndromes; p :s 0.02. Moreover, within the subgroup of patients with unsta-
ble coronary syndromes, TF protein was detected in 14 (61 %) of 23 patients
with de-novo lesions versus only 1 (10%) of 10 patients with rest angina from
a restenosis lesion; p :s 0.01. An additional 7 patients with stable coronary
syndromes due to a restenosis lesion were also all negative for TF, for an
overall incidence of only 1 (6%1 of 17 restenosis lesions.
In conclusion, tissue factor is readily detected in atherectomy specimens
from de-novo lesions in patients with unstable coronary syndromes, sug-
gesting a role for this protein in the pathogenesis of this disease process.
Conversely, tissue factor is rarely detected in patients with restenosis lesions
even if the clinical presentation is an unstable coronary syndrome. These re-
sults may have implications in regard to the management of patients with
unstable angina from de-novo lesions and all patients with recurrent symp-
toms from restenosis lesions.
In a subset of pts with restenosis after PTA, repeat balloon angioplasty (N
= 14) resulted in a 100% restenosis; however, central vein stenting (N = 8)
was associated with recurrent restenosis in only 38% (p < 0.0005).
Conclusion: PTA of central venous occlusions in dialysis patients is asso-
ciated with a very high restenosis rate, especially in patients with prior an-
gioplasty. Because stenting has an excellent acute success rate and lower
restenosis rate, it appears to be a better treatment option in these patients.
Atherosclerotic plaque disruption and thrombosis are now recognized as ma-
jor causes of acute coronary syndromes. Tissue factor may playa central role
in linking plaque disruption to thrombus formation. We utilized an atheroscle-
rotic rabbit model of plaque disruption and thrombosis to determine the re-
lationship between luminal surface tissue factor and arterial thrombi.
Triggering was attempted in 11 atherosclerotic rabbits and 5 normal rab-
bits using only intraperitoneal Russell viper venom (a procoagulant) and in-
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Increased Tissue Factor at Sites of Thrombosis in an
Atherosclerotic Animal Model
Michael T Johnstone, Jaime E. Murillo, Richard Dalfen, Tom Daly, Aruna Pawashe,
William Konigsberg, Michael Ezekowitz, William Quist, Tom Aretz, James E. Muller,
Geoffrey H. Tofler, Victor Gurewich Institute for Prevention of Cardiovascular Disease,
Cardiovascular Division, Deaconess Hospital, Boston, MA; Harvard Medical School,
Boston, MA; Yale School of Medicine, New Haven, CT
